Jennifer M. Kress-Bennett

Suggest Changes
Learn More
BACKGROUND There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis (MS) patients receiving interferon beta (IFN-β). Thus the objective of this study was(More)
  • 1